Non-Exosomal and Exosome-Derived miRNAs as Promising Biomarkers in Canine Mammary Cancer

• Published in: Life (Basel, Switzerland) Vol. 12; no. 4; p. 524
• Main Authors: Petroušková, Patrícia, Hudáková, Nikola, Maloveská, Marcela, Humeník, Filip, Cizkova, Dasa
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-04-2022; MDPI
• Series: Life (Basel, Switzerland)
• Subjects: Age; Antigens; biomarker; Biomarkers; Biopsy; Bone cancer; Breast cancer; Cancer; canine; Classification; Classification schemes; Colorectal cancer; Cyclin-dependent kinases; Dogs; Epidermal growth factor; Estrogens; exosome; Exosomes; Gastric cancer; Hormones; Kinases; Life Sciences; Lung cancer; mammary cancer; Mammary gland; miRNA; Neoplasia; Ovaries; Pain; Post-transcription; Proteins; Review; Tumor cell lines; Tumors; Veterinary medicine; mammary cancer; miRNA; canine; biomarker; exosome
• ISSN: 2075-1729; 2075-1729
• DOI: 10.3390/life12040524

Canine mammary cancer (CMC), similar to human breast cancer (HBC) in many aspects, is the most common neoplasm associated with significant mortality in female dogs. Due to the limited therapy options, biomarkers are highly desirable for early clinical diagnosis or cancer progression monitoring. Since the discovery of microRNAs (miRNAs or miRs) as post-transcriptional gene regulators, they have become attractive biomarkers in oncological research. Except for intracellular miRNAs and cell-free miRNAs, exosome-derived miRNAs (exomiRs) have drawn much attention in recent years as biomarkers for cancer detection. Analysis of exosomes represents a non-invasive, pain-free, time- and money-saving alternative to conventional tissue biopsy. The purpose of this review is to provide a summary of miRNAs that come from non-exosomal sources (canine mammary tumor, mammary tumor cell lines or canine blood serum) and from exosomes as promising biomarkers of CMC based on the current literature. As is discussed, some of the miRNAs postulated as diagnostic or prognostic biomarkers in CMC were also altered in HBC (such as miR-21, miR-29b, miR-141, miR-429, miR-200c, miR-497, miR-210, miR-96, miR-18a, miR19b, miR-20b, miR-93, miR-101, miR-105a, miR-130a, miR-200c, miR-340, miR-486), which may be considered as potential disease-specific biomarkers in both CMC and HBC.